ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Pulmonary Disease

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

10,098Medicare Part D Prescriptions Filled, Including Refills

Rank: 11 out of 568

$730K Total Retail Price of All Prescriptions

Rank: 24 out of 568

566 Patients Receiving at Least One Drug in Part D
85%Patients 65 Years and Older
29% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in New York
Lower avg

Schedule Two
Controlled Substances

N/A

Schedule Three
Controlled Substances

6% of this provider’s 566 patients filled at least one prescription for a schedule three drug, compared to an average of 1%.

Risky Drugs to Seniors

1% of this provider’s 8,975 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 0%.

Brand Name Drugs

37% of this provider’s prescriptions were for brand-name drugs, compared to an average of 56%.

Prescription Price

$72 was the average price of a prescription from this provider, compared to $126 among peers.

Prescriptions per Patient

18 is the average number of prescriptions (including refills) per patient, compared to an average of 11.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in New York
SIMVASTATIN 409 368 1 3
ATORVASTATIN CALCIUM 377 339 2 15
FUROSEMIDE 316 313 3 11
AMLODIPINE BESYLATE 309 265 4 6
LEVOTHYROXINE SODIUM 291 270 5 10
METOPROLOL SUCCINATE 271 241 6 18
METFORMIN HCL 258 229 7 13
ZOLPIDEM TARTRATE 252 210 8 20
CRESTOR 247 236 9 31
WARFARIN SODIUM 220 220 10 22
LISINOPRIL 211 181 11 12
METOPROLOL TARTRATE 198 186 12 14
SYNTHROID 182 159 13 47
TRIAMTERENE-HCTZ 170 149 14 68
OMEPRAZOLE 167 143 15 8
LIPITOR 166 157 16 50
ALENDRONATE SODIUM 132 120 17 30
ENALAPRIL MALEATE 126 119 18 26
ATENOLOL 123 109 19 25
HYDROCHLOROTHIAZIDE 121 118 20 19
SERTRALINE HCL 120 106 21 61
POTASSIUM CHLORIDE 120 116 21 52
ADVAIR DISKUS 118 112 23 2
GLIMEPIRIDE 116 107 24 55
TRICOR 111 91 25 160
DIOVAN 107 82 26 29
TAMSULOSIN HCL 104 94 27 35
RAMIPRIL 101 87 28 58
AZITHROMYCIN 100 90 29 17
KLOR-CON M20 94 94 30 152
CLOPIDOGREL 90 76 31 38
DONEPEZIL HCL 88 88 32 34
ZETIA 85 66 33 84
JANUVIA 81 74 34 32
PLAVIX 81 77 34 44
PREDNISONE 80 78 36 4
KLOR-CON M10 78 75 37 178
NEXIUM 74 52 38 27
VYTORIN 71 71 39 240
KLOR-CON 10 71 71 39 180
RANITIDINE HCL 65 51 41 41
DIGOXIN 64 62 42 85
ALLOPURINOL 64 64 42 71
SPIRIVA 62 60 44 1
DIOVAN HCT 62 61 44 45
PRAVASTATIN SODIUM 61 46 46 33
CITALOPRAM HBR 58 54 47 51
LOSARTAN-HYDROCHLOROTHIAZIDE 57 50 48 42
FENOFIBRATE 57 51 48 82
LOSARTAN POTASSIUM 55 52 50 23
LOVAZA 54 50 51 73
GABAPENTIN 53 50 52 36
ESCITALOPRAM OXALATE 52 36 53 132
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Feb. 17, 2010.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.